Lanreotide In Polycystic Kidney Disease Study

Trial Profile

Lanreotide In Polycystic Kidney Disease Study

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2017

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Autosomal dominant polycystic kidney disease; Kidney disorders
  • Focus Therapeutic Use
  • Acronyms LIPS
  • Most Recent Events

    • 20 Dec 2017 Planned End Date changed from 1 Apr 2019 to 1 Sep 2019.
    • 20 Dec 2017 Planned primary completion date changed from 1 Oct 2018 to 1 Sep 2019.
    • 22 Nov 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top